The Effect of Guilingji Capsules on Vascular Mild Cognitive Impairment: A Randomized, Double-Blind, Controlled Trial
Table 2
Comparison of scale scores and serum indexes before treatment in the two groups.
Scale
GLJC group (n = 37)
Ginkgo group (n = 45)
value
MoCA, mean (SD)
20 (2.43)
20.47 (2.90)
0.438
MMSE, median (IQR)
24 (24-25)
24 (24-25)
0.578
ADAS-Cog, mean (SD)
21.54 (7.30)
20.63 (9.08)
0.624
CM-SS, mean (SD)
19.84 (5.65)
20 (4.83)
0.889
HIS, median (IQR)
9 (8–10.5)
9 (8–11)
0.985
ADL, median (IQR)
23 (21–25)
23 (22–25)
0.921
CDR, median (IQR)
0.5 (0–0.5)
0 (0–0.5)
0.307
Ach (pmol/mL), median (IQR)
135.63 (95.32–224.60)
130.84 (85.84–200.94)
0.783
AchE (pg/mL), median (IQR)
291.85 (264.54–348.78)
305.24 (270.62–371.81)
0.418
Hcy (µmol/L), mean (SD)
12.62 (3.06)
11.80 (2.57)
0.187
hs-CRP (mg), median (IQR)
3.59 (1.92–4.98)
3.50 (2.55–5.17)
0.830
Note: the normally distributed MoCA, ADAS-Cog, and CM-SS scores and the Hcy levels are expressed as mean (SD). The nonnormally distributed variables are expressed as median (IQR).
